Leptin Composition Modulating Tau Phosphorylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective methods for modulating phosphorylated tau accumulation in the cerebrospinal fluid, which is a hallmark of progressive cognitive disorders such as Alzheimer's disease and other neurodegenerative conditions, leading to neuronal damage and cognitive decline.
Innovation Solution
Administering a composition comprising a phosphorylated tau accumulation-modulating amount of a leptin composition, which can include leptin, leptin mimics, derivatives, or agonists, in combination with a pharmaceutically acceptable carrier to modulate tau phosphorylation levels in the cerebrospinal fluid, potentially in conjunction with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of cognitive disorders is provided, but effective modulation of phosphorylated tau accumulation in cerebrospinal fluid is not achieved
Solution Approach 1:
The patent applies parameter changes by administering leptin or leptin mimics at specific dosages (e.g., 0.1-10 mg/kg body weight) to modulate the phosphorylation state of tau protein. This changes the biochemical parameter of tau phosphorylation levels in cerebrospinal fluid, transforming ineffective current therapies into effective treatment by altering the key pathological parameter of tau accumulation
Solution Approach 2:
The patent introduces leptin and leptin mimics as intermediary substances that mediate between the administration system and the pathological tau protein. These intermediaries bind to receptors and trigger signaling cascades that ultimately modulate tau phosphorylation, providing a mechanistic bridge that current therapies lack
2Stability of the object's composition
If phosphorylated tau accumulation is not modulated, then current treatment protocols can be maintained, but progression of cognitive disorders continues and cognitive resilience is not improved
Solution Approach 1:
The patent applies preliminary action by administering leptin or leptin mimics before significant neuronal damage occurs. The treatment targets early pathological changes in tau phosphorylation, preventing the progression to advanced neurodegeneration. This proactive approach maintains treatment stability while improving reliability of progression control by intervening at an earlier stage
3Ease of operation
If neurofibrillary tangle pathology is not targeted, then general symptomatic treatment can be provided, but underlying cause of cognitive decline is not addressed
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of tau phosphorylation and neurofibrillary tangle formation. By focusing on this extracted pathological element rather than providing general symptomatic treatment, the patent achieves both simplicity in targeting a single mechanism and high reliability in addressing the underlying cause of cognitive decline
Data Source
AI summary
The described invention provides methods for treating or preventing progression of a progressive cognitive disease, disorder or condition, and methods for improving resilience of cognitive function in a subject in need thereof.